高知大学医学部眼科学講座では安心、納得、信頼される最前の眼科治療をご提供します。

  • HOME » 
  • 新着情報 » 
  • 学術論文 2019年の原著・英文を更新しました。高知大学医学部 眼科学講座

眼科学講座よりお知らせ

2019.7.8  学術論文 2019年の原著・英文を更新しました。

【原著,英文】

1. Asada Y, Okano M, Ishida W, Iwamoto S, Fukuda K, Hirakata T, Tada N, Fukushima A, Ebihara N, Kudo A, Matsuda A.  Periostin deletion suppresses late-phase response in mouse experimental allergic conjunctivitis.  Allergol Int.2019 Apr;68(2):233-239.

2. Minami T, Ishida W, Hino S, Matsunaga T, Fukushima A, Yamagami S. In vitro and in vivo performance of epinastine hydrochloride releasing contact lenses. PLOS ONE, Published: January 30, 2019. https://doi.org/10.1371/journal.pone.0210362

3. Saito H, Kagami S, Mishima K, Mataki N, Fukushima A,Araie M. Long term side effects including blepharitis leading to termination of 0.4% ripasudil, a rho-kinase inhibitor, in glaucoma patients of a clinical setting. J Glaucoma. 2019 Feb 1.doi:10.1097/IJG.0000000000001203.[Epub ahead of print]

4. Sakamoto E, Ishida W , Sumi T, Kishimoto T, Tada K, Fukuda K, Yoneda T, Kuroiwa H, Terao E, Fujisawa Y, Nakakura S, Jian K, Okumichi H, Kiuchi Y,  Fukushima A. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial. Sci Rep. 2019 Mar 6;9(1):3755.doi:10.1038/s41598-019-40255-9.

5. Shoji J, Ohashi Y, Fukushima A, Miyazaki D, Uchio E, Takamura E, Fujishima H, Namba K, Kumagai N, Ebihara N, Okamoto S. Topical tacrolimus for chronic allergic conjunctival disease with and without atopic dermatitis. Curr Eye Res,2019 July; 44(7), 796-805.

6.Masumoto H, Tabuchi H, Yoneda T, Nakakura S, Ohsugi H, TSumi T, Fukushima A. Severity classification of conjunctival hyperaemia by deep neural network ensembles. J Ophthalmol, in press.

7.Yamana Y, Fukuda K, Ko R, Uchio E.Local allergic conjunctivitis: a phenotype of allergic conjunctivitis.International Ophthalmology, in press

【症例報告,英文】

1.Fukuda K, Ishida W, Kishimoto T, Fukushima A. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int, in press.